Price Alert

Cogent Biosciences Inc. (COGT)

NASDAQ: COGT · Real-Time Price · USD

15.76

1.01 (6.85%)

At close: Oct 03, 2025, 3:59 PM

16.21

2.87%

After-hours: Oct 03, 2025, 06:49 PM EDT

6.85% (1D)

Bid	14.5
Market Cap	2.2B
Revenue (ttm)	4.29M
Net Income (ttm)	-284.08M
EPS (ttm)	-2.08
PE Ratio (ttm)	-7.58
Forward PE	-8.02
Analyst	Buy
Dividends	n/a

Ask	16.14
Volume	2,041,074
Avg. Volume (20D)	2,663,107
Open	14.88
Previous Close	14.75
Day's Range	14.80 - 16.01
52-Week Range	3.72 - 16.00
Beta	0.30
Ex-Dividend Date	n/a

About COGT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol COGT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for COGT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+9%

Cogent Biosciences shares are trading higher after... Unlock content with Pro Subscription

2 months ago

+6.34%

Cogent Biosciences shares are trading higher after the company announced $200 million public offering.

News

1 month ago · seekingalpha.com

Cogent Biosciences, Inc. (COGT) Presents At Citi's Biopharma Back To School Conference Transcript

Cogent Biosciences, Inc. (NASDAQ:COGT ) Citi's Biopharma Back to School Conference September 3, 2025 9:00 AM EDT Company Participants Andrew Robbins - President, CEO & Director Conference Call Partici...

2 months ago · 247wallst.com

2 Biotech and 2 Tech Stocks Insiders Are Scooping Up Now

Insider buying has been slow this month, as buy windows close ahead of the new earnings-reporting season.

2 months ago · seekingalpha.com

Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results

I have upgraded Cogent Biosciences, Inc. to Strong Buy after positive SUMMIT trial data for bezuclastinib in non-advanced systemic mastocytosis patients. COGT plans to submit an NDA for bezuclastinib ...

2 months ago · zacks.com

COGT Stock Soars on Phase III Systemic Mastocytosis Study Success

Cogent Biosciences stock jumps 23.4% after bezuclastinib hits primary and all key secondary endpoints in a phase III systemic mastocytosis study.

2 months ago · benzinga.com

Why Is Cogent Biosciences Stock Trading Higher On Monday?

Cogent Biosciences, Inc.‘s COGT bezuclastinib showed meaningful clinical benefit for patients with non-advanced systemic mastocytosis, a rare and debilitating immune disorder.